Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

IMPORTANCE: Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release syndrome in patients with severe COVID-19 illness. OBJEC...

詳細記述

保存先:
書誌詳細
出版年:JAMA Intern Med
主要な著者: Gupta, Shruti, Wang, Wei, Hayek, Salim S., Chan, Lili, Mathews, Kusum S., Melamed, Michal L., Brenner, Samantha K., Leonberg-Yoo, Amanda, Schenck, Edward J., Radbel, Jared, Reiser, Jochen, Bansal, Anip, Srivastava, Anand, Zhou, Yan, Finkel, Diana, Green, Adam, Mallappallil, Mary, Faugno, Anthony J., Zhang, Jingjing, Velez, Juan Carlos Q., Shaefi, Shahzad, Parikh, Chirag R., Charytan, David M., Athavale, Ambarish M., Friedman, Allon N., Redfern, Roberta E., Short, Samuel A. P., Correa, Simon, Pokharel, Kapil K., Admon, Andrew J., Donnelly, John P., Gershengorn, Hayley B., Douin, David J., Semler, Matthew W., Hernán, Miguel A., Leaf, David E.
フォーマット: Artigo
言語:Inglês
出版事項: American Medical Association 2021
主題:
Original Investigation
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7577201/
https://ncbi.nlm.nih.gov/pubmed/33080002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2020.6252
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料